`To:
`
`Cc:
`Subject:
`Date:
`
`Malik, Jitty
`Fisher, Stanley; Mahaffy, Shaun; Pacchioli, Alissa M.; West, Christopher W.; Radeke, Heike Simone; Pacchioli,
`Alissa M.; Van Buskirk, Tedd W.; Teschner, Michael H.; Faegenburg, Russell W.; Wong, Jovial; Fundakowski,
`Claire (CFundakowski@winston.com); Fischer, Sarah; Zullow, Keith A
`Merck-Sitagliptin
`RE: IPR2020-00040, IPR2020-01045, IPR2020-01060, IPR2020-01072
`Thursday, July 2, 2020 8:51:25 AM
`
`Stan,
`
`That will work.
`
`Jitty
`
`Jitendra (“Jitty”) Malik Ph.D.
`Partner
`Katten
`Katten Muchin Rosenman LLP
`550 S. Tryon Street, Suite 2900 | Charlotte, NC 28202-4213
`direct +1.704.344.3185
`jitty.malik@katten.com | katten.com
`
`From: Fisher, Stanley <SFisher@wc.com>
`Sent: Thursday, July 2, 2020 8:49 AM
`To: Malik, Jitty <jitty.malik@katten.com>; Mahaffy, Shaun <SMahaffy@wc.com>; Pacchioli, Alissa M.
`<alissa.pacchioli@katten.com>; West, Christopher W. <christopher.west@katten.com>; Radeke,
`Heike Simone <heike.radeke@katten.com>; Pacchioli, Alissa M. <alissa.pacchioli@katten.com>; Van
`Buskirk, Tedd W. <tvanbuskirk@lernerdavid.com>; Teschner, Michael H.
`<mteschner@lernerdavid.com>; Faegenburg, Russell W. <rfaegenburg@lernerdavid.com>; Wong,
`Jovial <JWong@winston.com>; Fundakowski, Claire (CFundakowski@winston.com)
`<CFundakowski@winston.com>; Fischer, Sarah <SFischer@goodwinlaw.com>; Zullow, Keith A
`<KZullow@goodwinlaw.com>
`Cc: Merck-Sitagliptin <MerckSitagliptin@wc.com>
`Subject: RE: IPR2020-00040, IPR2020-01045, IPR2020-01060, IPR2020-01072
`
`EXTERNAL EMAIL – EXERCISE CAUTION
`Jitty,
`
`Yes, can we say Thurs. Aug. 6?
`
`Thanks,
`Stan
`
`Stanley E. Fisher
`Williams & Connolly LLP
`725 Twelfth Street, N.W., Washington, DC 20005
`(P) 202-434-5289 |(F) 202-434-5029
`SFisher@wc.com | www.wc.com/sfisher
`
`Merck Sharp & Dohme Corp. Exhibit 2035
`Teva Pharmaceuticals Inc. v. Merck Sharp & Dohme Corp.
`IPR2020-01045
`Page 1
`
`
`
`
`From: Malik, Jitty <jitty.malik@katten.com>
`Sent: Wednesday, July 01, 2020 10:55 AM
`To: Fisher, Stanley <SFisher@wc.com>; Mahaffy, Shaun <SMahaffy@wc.com>; Pacchioli, Alissa M.
`<alissa.pacchioli@katten.com>; West, Christopher W. <christopher.west@katten.com>; Radeke,
`Heike Simone <heike.radeke@katten.com>; Pacchioli, Alissa M. <alissa.pacchioli@katten.com>; Van
`Buskirk, Tedd W. <tvanbuskirk@lernerdavid.com>; Teschner, Michael H.
`<mteschner@lernerdavid.com>; Faegenburg, Russell W. <rfaegenburg@lernerdavid.com>; Wong,
`Jovial <JWong@winston.com>; Fundakowski, Claire (CFundakowski@winston.com)
`<CFundakowski@winston.com>; Fischer, Sarah <SFischer@goodwinlaw.com>; Zullow, Keith A
`<KZullow@goodwinlaw.com>
`Cc: Merck-Sitagliptin <MerckSitagliptin@wc.com>
`Subject: RE: IPR2020-00040, IPR2020-01045, IPR2020-01060, IPR2020-01072
`
`Stan,
`
`Does Merck have any availability August 5th-7th?
`
`Jitty
`
`Jitendra (“Jitty”) Malik Ph.D.
`Partner
`Katten
`Katten Muchin Rosenman LLP
`550 S. Tryon Street, Suite 2900 | Charlotte, NC 28202-4213
`direct +1.704.344.3185
`jitty.malik@katten.com | katten.com
`
`From: Fisher, Stanley <SFisher@wc.com>
`Sent: Wednesday, July 1, 2020 8:54 AM
`To: Malik, Jitty <jitty.malik@katten.com>; Mahaffy, Shaun <SMahaffy@wc.com>; Pacchioli, Alissa M.
`<alissa.pacchioli@katten.com>; West, Christopher W. <christopher.west@katten.com>; Radeke,
`Heike Simone <heike.radeke@katten.com>; Pacchioli, Alissa M. <alissa.pacchioli@katten.com>; Van
`Buskirk, Tedd W. <tvanbuskirk@lernerdavid.com>; Teschner, Michael H.
`<mteschner@lernerdavid.com>; Faegenburg, Russell W. <rfaegenburg@lernerdavid.com>; Wong,
`Jovial <JWong@winston.com>; Fundakowski, Claire (CFundakowski@winston.com)
`<CFundakowski@winston.com>; Fischer, Sarah <SFischer@goodwinlaw.com>; Zullow, Keith A
`<KZullow@goodwinlaw.com>
`Cc: Merck-Sitagliptin <MerckSitagliptin@wc.com>
`Subject: RE: IPR2020-00040, IPR2020-01045, IPR2020-01060, IPR2020-01072
`
`EXTERNAL EMAIL – EXERCISE CAUTION
`Counsel,
`
`Merck reserves all rights to oppose joinder, and if joinder is ordered, to seek party discovery in
`
`Merck Sharp & Dohme Corp. Exhibit 2035
`Teva Pharmaceuticals Inc. v. Merck Sharp & Dohme Corp.
`IPR2020-01045
`Page 2
`
`
`
`advance of the deposition of Dr. Chorghade, along with a reasonable adjustment to the schedule to
`accommodate party discovery. Do any of the other Petitioners (Teva, Sun, or DRL) intend to respond
`to my June 26 letter, which was an attempt to narrow the issues and potentially obviate an
`opposition to joinder?
`
`Assuming the Board denies the joinder motions, Merck has no objection to a remote deposition for
`Dr. Chorghade at the end of July. July 22 does not work for Merck; we are available the following
`week on any of July 29-31. Please let me know if one of those days works for Mylan to tentatively
`schedule Dr. Chorghade’s deposition.
`
`Thank you,
`Stan
`
`Stanley E. Fisher
`Williams & Connolly LLP
`725 Twelfth Street, N.W., Washington, DC 20005
`(P) 202-434-5289 |(F) 202-434-5029
`SFisher@wc.com | www.wc.com/sfisher
`
`From: Malik, Jitty <jitty.malik@katten.com>
`Sent: Monday, June 29, 2020 1:35 PM
`To: Mahaffy, Shaun <SMahaffy@wc.com>; Pacchioli, Alissa M. <alissa.pacchioli@katten.com>; West,
`Christopher W. <christopher.west@katten.com>; Radeke, Heike Simone
`<heike.radeke@katten.com>; Pacchioli, Alissa M. <alissa.pacchioli@katten.com>; Van Buskirk, Tedd
`W. <tvanbuskirk@lernerdavid.com>; Teschner, Michael H. <mteschner@lernerdavid.com>;
`Faegenburg, Russell W. <rfaegenburg@lernerdavid.com>; Wong, Jovial <JWong@winston.com>;
`Fundakowski, Claire (CFundakowski@winston.com) <CFundakowski@winston.com>; Fischer, Sarah
`<SFischer@goodwinlaw.com>; Zullow, Keith A <KZullow@goodwinlaw.com>
`Cc: Merck-Sitagliptin <MerckSitagliptin@wc.com>
`Subject: RE: IPR2020-00040, IPR2020-01045, IPR2020-01060, IPR2020-01072
`
`Counsel,
`
`Mylan is in receipt of your letter. To that end, and speaking only on behalf of Mylan, Mylan remains
`opposed to any change in the current schedule. See IPR2020-00040 (Paper 32). To that end, Dr.
`Chorghade will be made available for his deposition on July 22nd. Due to the current COVID
`pandemic, and for the health and safety off all concerned, Dr. Chorghade will be made available only
`for a remote deposition. Please let Mylan know if Merck has any objection to proceeding on this
`date.
`
`Thanks,
`
`Jitty
`
`Jitendra (“Jitty”) Malik Ph.D.
`Partner
`
`Merck Sharp & Dohme Corp. Exhibit 2035
`Teva Pharmaceuticals Inc. v. Merck Sharp & Dohme Corp.
`IPR2020-01045
`Page 3
`
`
`
`Katten
`Katten Muchin Rosenman LLP
`550 S. Tryon Street, Suite 2900 | Charlotte, NC 28202-4213
`direct +1.704.344.3185
`jitty.malik@katten.com | katten.com
`
`From: Mahaffy, Shaun <SMahaffy@wc.com>
`Sent: Friday, June 26, 2020 5:22 PM
`To: Malik, Jitty <jitty.malik@katten.com>; Pacchioli, Alissa M. <alissa.pacchioli@katten.com>; West,
`Christopher W. <christopher.west@katten.com>; Radeke, Heike Simone
`<heike.radeke@katten.com>; Malik, Jitty <jitty.malik@katten.com>; Pacchioli, Alissa M.
`<alissa.pacchioli@katten.com>; Van Buskirk, Tedd W. <tvanbuskirk@lernerdavid.com>; Teschner,
`Michael H. <mteschner@lernerdavid.com>; Faegenburg, Russell W.
`<rfaegenburg@lernerdavid.com>; Wong, Jovial <JWong@winston.com>; Fundakowski, Claire
`(CFundakowski@winston.com) <CFundakowski@winston.com>; Fischer, Sarah
`<SFischer@goodwinlaw.com>; Zullow, Keith A <KZullow@goodwinlaw.com>
`Cc: Merck-Sitagliptin <MerckSitagliptin@wc.com>
`Subject: IPR2020-00040, IPR2020-01045, IPR2020-01060, IPR2020-01072
`
`EXTERNAL EMAIL – EXERCISE CAUTION
`Counsel,
`
`Please see the attached correspondence.
`
`Regards,
`Shaun
`
`Shaun P. Mahaffy
`Associate | Williams & Connolly LLP
`725 Twelfth Street, N.W., Washington, DC 20005
`(P) 202-434-5554 | (F) 202-434-5029
`smahaffy@wc.com | www.wc.com
`
`
`
`This message and any attachments are intended only for the addressee and may contain information that is
`privileged and confidential. If you have received this message in error, please do not read, use, copy, distribute, or
`disclose the contents of the message and any attachments. Instead, please delete the message and any attachments
`and notify the sender immediately. Thank you.
`===========================================================
`CONFIDENTIALITY NOTICE:
`This electronic mail message and any attached files contain information
`intended for the exclusive
`use of the individual or entity to whom it is addressed and may contain
`information that is
`proprietary, privileged, confidential and/or exempt from disclosure under
`applicable law. If you
`are not the intended recipient, you are hereby notified that any viewing,
`copying, disclosure or
`
`Merck Sharp & Dohme Corp. Exhibit 2035
`Teva Pharmaceuticals Inc. v. Merck Sharp & Dohme Corp.
`IPR2020-01045
`Page 4
`
`
`
`distribution of this information may be subject to legal restriction or
`sanction. Please notify
`the sender, by electronic mail or telephone, of any unintended recipients
`and delete the original
`message without making any copies.
`===========================================================
`NOTIFICATION: Katten Muchin Rosenman LLP is an Illinois limited liability
`partnership that has
`elected to be governed by the Illinois Uniform Partnership Act (1997).
`===========================================================
`
`
`Merck Sharp & Dohme Corp. Exhibit 2035
`Teva Pharmaceuticals Inc. v. Merck Sharp & Dohme Corp.
`IPR2020-01045
`Page 5
`
`